07:32 EDT MannKind (MNKD) to acquire scPharmaceuticals (SCPH) for up to $6.35 per share in cash
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 55% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on MNKD:
- MannKind’s Growth Potential and Stability: Buy Rating Reinforced by Pipeline Progress and Strategic Catalysts
- MannKind Corporation’s Earnings Call Highlights Growth and Challenges
- MannKind Corporation Reports Q2 2025 Financial Growth
- Promising Outlook for MannKind: Buy Rating Justified by Clinical Progress and Financial Strength
- MannKind’s Strategic Growth Potential and Undervalued Stock: A Buy Rating Amid Market Overreactions